798563-50-5

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(2-fluoro-5-Methoxyphenyl)acetic acid is used as a building block in pharmaceutical research for its potential to contribute to the development of new drugs. Its unique structure and properties facilitate the exploration of structure-activity relationships in medicinal chemistry, aiding in the design of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(2-fluoro-5-Methoxyphenyl)acetic acid is utilized as a key intermediate, enabling the creation of a variety of complex organic molecules. Its presence in the synthesis process can influence the reactivity and selectivity of the resulting compounds, which is crucial for the advancement of organic chemistry.
Used in Medicinal Chemistry:
2-(2-fluoro-5-Methoxyphenyl)acetic acid is used as a valuable tool in medicinal chemistry for studying the structure-activity relationships of various compounds. Its incorporation into different molecular frameworks can provide insights into how structural modifications affect the biological activity of the compounds, which is essential for optimizing drug efficacy and safety.
Used in Drug Development for Inflammatory and Pain Conditions:
Given its anti-inflammatory and analgesic properties, 2-(2-fluoro-5-Methoxyphenyl)acetic acid is used as a potential candidate for the development of medications aimed at treating inflammatory and pain-related conditions. Its pharmacological activities suggest that it could be a component of new therapeutic agents that offer relief from these symptoms.

Upstream product

• 2338-54-7 4-fluoro-3-methylanisol 
• 143-33-9 sodium cyanide 
• 105728-90-3 2-fluoro-5-methoxybenzaldehyde 
• 1418126-43-8 2,2,2-trichloro-1-(2-fluoro-5-methoxyphenyl)ethanol 
• 672931-28-1 2-(2-fluoro-5-methoxyphenyl)acetonitrile 

Downstream Products

• 1344688-70-5 C₂₂H₂₆FNO₆ 
• 149029-89-0 2-(2-fluoro-5-hydroxyphenyl)acetic acid 
• 459215-67-9 2-(5-(benzyloxy)-2-fluorophenyl)acetic acid 
• 1418126-44-9 2-(5-(benzyloxy)-2-fluorophenyl)acetyl chloride 
• 1418126-21-2 3-((6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-4-fluorophenol 
• 1418126-45-0 2-(5-(benzyloxy)-2-fluorophenyl)-N-(3,4-dimethoxyphenethyl)-N-methylacetamide 
• 1418126-47-2 1-(5-(benzyloxy)-2-fluorobenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 1344688-82-9 C₂₂H₂₄FNO₅ 
• 798563-51-6 1-(2-fluoro-5-methoxybenzyl)-4-ethoxycarbonyl-6,7-dimethoxyisoquinoline 
• 798563-57-2 C₂₀H₁₉FN₄O₃ 
• 798563-55-0 1-(2-fluoro-5-methoxybenzyl)-4-hydroxymethyl-6,7-dimethoxyisoquinoline 
• 798563-56-1 4-chloromethyl-1-(2-fluoro-5-methoxy-benzyl)-6,7-dimethoxy-isoquinoline 

Relevant academic research and scientific papers

COMPOUNDS AND THEIR METHODS OF USE

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF

Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.

COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.

Inverting the regioselectivity of the berberine bridge enzyme by employing customized fluorine-containing substrates

Fluorine is commonly applied in pharmaceuticals to block the degradation of bioactive compounds at a specific site of the molecule. Blocking of the reaction center of the enzyme-catalyzed ring closure of 1,2,3,4- tetrahydrobenzylisoquinolines by a fluoro moiety allowed redirecting the berberine bridge enzyme (BBE)-catalyzed transformation of these compounds to give the formation of an alternative regioisomeric product namely 11-hydroxy-functionalized tetrahydroprotoberberines instead of the commonly formed 9-hydroxy-functionalized products. Alternative strategies to change the regioselectivity of the enzyme, such as protein engineering, were not applicable in this special case due to missing substrate-enzyme interactions. Medium engineering, as another possible strategy, had clear influence on the regioselectivity of the reaction pathway, but did not lead to perfect selectivity. Thus, only substrate tuning by introducing a fluoro moiety at one potential reactive carbon center switched the reaction to the formation of exclusively one regioisomer with perfect enantioselectivity. Custom-made substrates: Employing customized substrates with a fluoro atom at the normally preferred reaction site switched the regioselectivity of the berberine-bridged enzyme. With this strategy, it was possible to get access to (S)-11-hydroxy-functionalized berbines in an asymmetric fashion by using the wild-type enzyme (see scheme). Copyright

FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF

The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

GFAT INHIBITORS

Compounds of formula (I) are provided as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.